RE:RE:RE:RE:PR more partial responses form Adlay trial...Since there has been no clinical trial assessing AN1004 in Chinese population, the Adlai Nortye bridging study (REO 026-1) was initiated to evaluate its safety and tolerability in combination with PTX in Chinese patients with HR+/HER2- advanced/metastatic breast cancer.
The conclusion of the study was that: To date (June 2, 2022), intravenous administration of AN1004 plus PTX was demonstrated to be safe and well-tolerated in Chinese patients with advanced/metastatic breast cancer, and demonstrates anti-tumor activity.
With the Adlai Nortye demonstrated findings te ONCY's IND-213 Phase 2 results have been confirmed in different population of patients that otherwise are not typically enrolled in traditional clinical trials. These Chinese results should further satisfy the FDA and EMA regulators "ask" who have been seeking greater diversity in clinical trial enrollment. This Chinese Phase 1 bridging trial ONCY has shown that ONCY's breast cancer clinical trials meet this FDA/EMA "ask".